Brochure
24 Aug 2026

SUREmAb Monoclonal Antibody Development, the Way it's Meant to Be

PDF 1.5 MB

SUREmAb preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 18 g/L) with a streamlined, lower-cost workflow. 

Content provided by our supplier

KBI Biopharma Inc.

  • Country/Region:
    United States
  • On CPHI since:
    2015
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer

Other Content from KBI Biopharma Inc. (11)